{"analyses":[{"ciLowerLimit":".71","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.09","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":".25","paramType":"Hazard Ratio (HR)","paramValue":".88","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"91.3","upperLimit":"93.5","value":"92.5"},{"groupId":"OG001","lowerLimit":"92","upperLimit":"94.2","value":"93.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2426"},{"groupId":"OG001","value":"2425"}],"units":"Participants"}],"description":"Duration of time from randomization to the first indication of invasive breast recurrence at a distant site. In the absence of an event, DRFI was censored at the date of last follow-up visit or date or death without distant recurrence.\\*\n\n\\*This endpoint replaced DDFS, which was specified in the protocol","dispersionType":"95% Confidence Interval","groups":[{"description":"Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)\n\nLetrozole: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously","id":"OG000","title":"Arm A: Continuous Letrozole"},{"description":"Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\\> 36 mo) plus 1 x 12 mo in yr 5 -\\> 48 months\n\nLetrozole: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\\> 36 mo) plus 1 x 12 mo in yr 5 -\\> 48 months","id":"OG001","title":"Arm B: Intermittent Letrozole"}],"paramType":"NUMBER","populationDescription":"Intention-to-treat","reportingStatus":"POSTED","timeFrame":"5-year estimates, reported at a median follow-up of 60 months","title":"Distant Recurrence-free Interval (DRFI)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}